Your search for "" did not match any of our events. Please try another event term or combination of terms and filters.
The American Society of Clinical Oncolgy (ASCO) is an international network of oncology professionals. The ASCO annual meeting offers premier scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide.
Caring for Every Patient, Learning from Every Patient
May 31–June 4, 2019
Highlights included oral presentations on:
Other highlights included poster presentations on topics such as complications of bone marrow transplantation, quality of life in survivors of young-adult cancers, first-line immunotherapy in advanced kidney cancer, the impact of national cooperative group studies, and more.
Delivering Discoveries: Expanding the Research of Precision Medicine
June 1–June 5, 2018
The American Association for Cancer Research (AACR) Annual Meeting program covers the latest discoveries across the spectrum of cancer research — from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy — and highlights the work of the best minds in research and medicine from institutions all over the world.
Integrative Cancer Science — Global Impact — Individualized Patient Care
March 29-April 3, 2019
Highlights included presentations on immunotherapy for solid tumors and updates on progress toward targeting the molecular drivers of lung, breast and prostate cancers.
Driving Innovative Cancer Science to Patient Care
April 14-18, 2018
This meeting put a spotlight on next-gen approaches to transgenic T-cell receptor, or TCR, immunotherapy, in which patients’ T cells are genetically engineered to produce a naturally occurring, cancer-targeting receptor called a TCR.
Presentation topics included:
The American Society of Hematology (ASH) is the worlds' largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases. The ASH annual meeting provides is an educational experience providing the opportunity to review thousands of scientific abstracts on the hottest topics in hematology.
Fred Hutch researchers presented talks and posters on a number of topics including CAR T-cell therapies, gene therapies, precision oncology, immune repair and transplantation
Transplantation physician-scientist Dr. Stephanie Lee became the new president of ASH, T-cell therapy pioneer Dr. Philip Greenberg gave the E. Donnall Thomas Lecture, and Dr. Andrew Cowan presented the latest on a new BCMA, or B-cell maturation antigen, CAR T-cell therapy for multiple myeloma.
December 1-4, 2018
The meeting featured the E. Donnall Thomas Lecture and Prize, created in 1992 and named after the late Nobel laureate who pioneered bone marrow transplantation at Fred Hutch and served as a past ASH president. The lecture and prize recognizes pioneering research achievements in hematology that have represented a paradigm shift or significant discovery in the field.
Other highligts included talks on cellular immunotherapies for leukemia, lymphoma and myeloma; gene therapy for hemoglobinopathies; hematopoietic cell transplantation; immune regeneration; and precision medicine for blood cancers.
The Transplantation & Cellular Therapy Meetings are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). The meeting features the E. Donnall Thomas Lecture, named after the late Nobel laureate who pioneered bone marrow transplantation at Fred Hutch. The lecture recognizes an eminent physician or scientist who has contributed meritoriously to the advancement of knowledge in blood and marrow transplantation.
February 20-24, 2019
Advances in Graft Engineering for GVHD Reduction
Marie Bleakley, M.D., Ph.D.
Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL
Jordan Gauthier, M.D., M.Sc.
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study (Poster)
Mohamed Sorror, M.D., M.Sc.
Factors Associated with Toxicity of CD19 CAR-T Cell Immunotherapy
Cameron J. Turtle, MBBS, Ph.D.
Creation of Personalized Patient Care Plans for HCT Survivors
Scott Baker, M.D., M.S.
Quantifying Cytomegalovirus-Specific T Cell Responses Prior to Hospital Discharge Allows Risk Stratification for Late Viral Reactivation after Allogenic Hematopoietic Cell Transplantation (Poster)
Michael Boeckh, M.D., Ph.D.